Øe-la[;k&135 ¼p&1½
jftLVªs'ku uEcj&,lŒ,lŒihŒ@,yŒ&
MCywå@,uŒihŒ&91@2014&16
ykblsUl Vw iksLV ,sV dUls'kuy jsV
—
¼ifjfu;r vkns'k½
[kk| lqj{kk ,oa vkS"kf/k iz'kklu vuqHkkx
la[;k 71@2023@1414@vV~Bklh-23-01vkS0-2023
y[kuÅ] 4 vxLr] 2023
&&&&&&
vf/klwpuk
^^Hkkjr dk lafo/kku** ds vuqPNsn 162 ds vUrxZr dk;Zikfydk 'kfDr;ksa dk iz;ksx djrs gq, jkT;iky }kjk mRrj izns'k QkekZL;qfVdy ,oa fpfdRlk midj.k m|ksx uhfr] 2023] dks iz[;kfir fd;k tkrk gSA
2&^mRrj izns'k QkekZL;qfVdy ,oa fpfdRlk midj.k m|ksx uhfr] 2023* fnukad 8 twu] 2023 ls vxys 5 o"kZ rd izHkkoh jgsxhA
mRrj izns'k QkekZL;qfVdy ,oa fpfdRlk midj.k m|ksx uhfr] 2023
1& &
bl uhfr dk mn~ns'; LFkkuh; mRiknu dks izksRlkfgr djuk] vuqla/kku ,oa fodkl dks c<+kok nsuk vkSj ukxfjdksa ds fy;s lLrh nokvksa dh miyC/krk esa lq/kkj djds jkT; ds QkekZL;qfVdy vkSj fpfdRlk midj.k m|ksx dk uohdj.k djuk gSA ;g uhfr jkT; esa QkekZL;qfVdy m|ksx ds fodkl ds fy, ,d vuqdwy okrkoj.k cukus ij dsfUær gS] ftldk mn~ns'; fofuekZ.k bdkb;ksa dh LFkkiuk ds fy, lfClMh vkSj Hkwfe vkoaVu tSls vusd izksRlkgu iznku djds bl {ks= esa fuos'k dks vk—"V djuk gSA uhfr dk mn~ns'; vR;k/kqfud lqfo/kkvksa dh LFkkiuk vkSj 'kS{kf.kd laLFkkuksa o vuqla/kku laLFkkuksa ds lkFk lg;ksx djds vuqla/kku vkSj fodkl ds fy, ,d etcwr ifjfLFkfrdh ra= cukuk gSA
mRrj izns'k esa QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= gky ds o"kksZa esa xfr idM+ jgk gS vkSj jkT; dh vkS|ksfxd uhfr esa ,d Qksdl {ks= ds :i esa bldh igpku dh xbZ gSA Qjojh 2023 esa vk;ksftr oSf'od fuos'kd f'k[kj lEesyu us bl {ks= dh laHkkoukvksa ij izdk'k Mkyk vkSj egRoiw.kZ fuos'k dks vk—"V fd;kA jkT; ljdkj ds iz;klksa ds QyLo:i 217 dEifu;ksa us QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= esa yxHkx :0 28]500 djksM+ ds fuos'k dk izLrko fn;k gSA bu fuos'kksa ls jkstxkj ds yxHkx 57]000 volj l`ftr gksus] LFkkuh; vFkZO;oLFkk dks c<+kok feyus vkSj bl {ks= ds fodkl esa ;ksxnku feyus dh vk'kk gSA 2 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= dks fo'ks"k rduhd] xq.koRrk fu;a=.k iz.kkyh dh vko';drk gksrh gS vkSj blfy, QkekZL;qfVdy vkSj fpfdRlk midj.k m|ksx LFkkfir djus ds fy, fo'ks"k ifjfLFkfrdh ra= dh vko';drk gksrh gSA
2& &
Hkkjrh; QkekZL;qfVdy m|ksx vR;Ur etcwr vkSj le`) gS rFkk orZeku esa bldk ewY; 41-7 fcfy;u vesfjdh M'yj gSA Hkkjr dk ?kjsyw QkekZL;qfVdy cktkj 2021 esa 42 vjc vesfjdh M'yj Fkk] ftlds 2024 rd 65 vjc vesfjdh M'yj vkSj vkxs 2030 rd 120 vjc vesfjdh M'yj rd igq¡pus dh laHkkouk gSA Hkkjrh; QkekZL;qfVdy cktkj ek=k ds vk/kkj ij QkekZL;qfVdy mRiknu ds ekeys esa fo'o esa rhljs vkSj ewY; ds fglkc ls 14osa LFkku ij gSA blesa 3]000 QkekZL;qfVdy daifu;ksa vkSj 10]500 fofuekZ.k bdkb;ksa dk usVodZ lfEefyr gSA Hkkjr esa ;w,l,QMh, }kjk vuqeksfnr bdkb;ksa dh nwljh lcls cM+h la[;k gSA dqy jktLo ds lanHkZ esa] tuojh 2022 esa cktkj esa 13-9% dh o`f) gqbZ gSA Hkkjr oSf'od tsusfjd nokvksa dk 20% fu;kZr djrk gS] ftlls ;g oSf'od Lrj ij tsusfjd nokvksa dk lcls cM+k vkiwfrZdrkZ cu x;k gSA Hkkjr fo'o esa fpfdRlk lkexzh dk 12oka lcls cM+k fu;kZrd gSA Hkkjrh; vkS"kf/k vkSj QkekZL;qfVdy fu;kZr foÙkh; o"kZ 2022 esa 24-60 fcfy;u Mkyj vkSj foÙkh; o"kZ 2021 esa 24-44 fcfy;u Mkyj FkkA Hkkjr 'kh"kZ 20 oSf'od fpfdRlk midj.k cktkjksa esa ls ,d gS vkSj ,f'k;k esa pkSFkk lcls cM+k fpfdRlk midj.k cktkj gSA
Hkkjrh; QkekZL;qfVdy m|ksx ds çeq[k [kaM tsusfjd vkS"kf/k;ksa] vksVhlh nok,a] ,ihvkbZ@cYd Mªx] Vhds] vuqca/k vuqla/kku ,oa fofuekZ.k] ck;ksflfeyj vkSj ck;ksy'ftDl gSaA Hkkjr ls nqfu;k Hkj ds 200 ls vf/kd jk"Vªksa rd QkekZL;qfVdy fu;kZr igq¡prk gS] ftlesa la;qä jkT; vesfjdk] if'peh ;wjksi] tkiku vkSj v'LVªsfy;k ds vR;f/kd fofu;fer cktkj lfEefyr gSaA
Hkkjr xzhuQhYM QkekZL;qfVdYl ifj;kstukvksa ds fy, lh/ks 100% rd dh ,QMhvkbZ dh is'kd'k djrk gSA czkmuQhYM QkekZL;qfVdYl ifj;kstukvksa ds fy, lh/ks 74% rd ,QMhvkbZ vuqeU; gS rFkk 'ks"k ljdkj ds vuqeksnu ds ek/;e ls gSA vçSy 2000 ls ekpZ 2022 dh vof/k ds nkSjku vkS"kf/k vkSj QkekZL;qfVdYl m|ksx esa lap;h ,QMhvkbZ bfDoVh çokg 19]405-35 fefy;u vesfjdh M'yj gSA
QkekZL;qfVdy vkSj fpfdRlk midj.k dh ?kjsyw fofuekZ.k {kerk dks c<+kok nsus ds fy, bl {ks= dks çksMD'ku fyaDM balsafVo ¼ih,yvkbZ½ ;kstuk dk Hkh leFkZu çkIr gSA ;kstuk dk foÙkh; ifjO;; :i;s 25]360 djksM+ gSA ;kstuk ds v/khu vkPNkfnr mRikn fuEuor~ gSa %& &1%&ckksQkekZL;qfVdYl] tfVy tsusfjd vkS"kf/k;k¡] isVsaV vkS"kf/k;k¡ ;k isVsaV lekfIr ds djhc vkus okyh vkS"kf/k;k¡] dksf'kdk&vk/kkfjr ;k thu Fksjsih mRikn] vukFk vkS"kf/k;k¡] fo'ks"k [kkyh dSIlwy] tfVy lgk;d inkFkZ] QkbVksQkekZL;qfVdYlA &2%&lfØ; QkekZ vo;o ¼,ihvkbZ½] çeq[k çkjafHkd lkexzh ¼ds,l,e½] Mªx b.VjehfM,V ¼MhvkbZ½A &3%&iqu#n~nsf'kr vkS"kf/k;k¡] v'Vks&bEwu vkS"kf/k;k¡] dSalj jks/kh vkS"kf/k;k¡] e/kqesg jks/kh vkS"kf/k;k¡] laØe.k jks/kh vkS"kf/k;k¡] ân; laca/kh vkS"kf/k;k¡] lkbdksVªksfid vkS"kf/k;k¡] ,aVh&jsVªksok;jy vkS"kf/k;k¡] fd.ou vk/kkfjr 4 ds,l,e@MhvkbZA
3 &
l{ke ikfjfLFkfrdh ra= vkSj 24 djksM+ ls vf/kd vkcknh ds lkFk mRrj çns'k] Hkkjr dh rhljh lcls cM+h vFkZO;oLFkk vkSj lcls cM+k miHkksDrk cktkj gSA lHkh Hkkjrh; jkT;ksa esa lcls vf/kd vkcknh okyk mRrj çns'k QkekZL;qfVdYl ds fy, lcls cM+k cktkj gSA e/;e oxZ dh vkcknh esa o`f) ds lkFk vf/kdka'k yksx xq.koRrkiw.kZ LokLF; lsok dk [kpZ mBk ldrs gSa] ftlls QkekZL;qfVdy {ks= esa vf/kd ekax iSnk gksrh gSA jkT; esa ,d f=Lrjh; lkoZtfud LokLF; lsok dk cqfu;knh
mRrj çns'k esa 71880 Fkksd vkS"kf/k foØ; ykblsal vkSj 108927 QqVdj vkS"kf/k foØ; ykblsal ds lkFk LokLF; laca/kh mRiknksa vkSj nokvksa ds fy, etcwr forj.k usVodZ gSA çns'k esa 619 fuekZ.k bdkb;k¡ gSa] ftuesa ,yksiSfFkd] gksE;ksiSfFkd] fpfdRlk midj.k vkSj lkSan;Z çlk/ku bdkb;k¡ lfEefyr gSa( vkSj lEiw.kZ ekuo jDr vkSj jDr ?kVdksa dh t:jr dks iwjk djus ds fy, jkT; esa 485 CyM cSad gSaA çns'k esa ubZ bdkb;ksa dh LFkkiuk dh vikj laHkkouk,¡ gSaA mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 3 3-1&
3-1-1&
jkT; ds ikl fofHkUu 'kSf{kd laLFkkuksa esa tu'kfä dh fu;fer vkiwfrZ vkSj çfrf"Br vuqla/kku laLFkku rFkk QkekZL;qfVDl foHkkx gSaA Mkå ,åihå tså vCnqy dyke çkfof/kd fo'ofo|ky;] y[kuÅ] mÙkj çns'k ls ch0 QkekZ0 fMxzh çnku djus okys 401 d'yst vkSj ,e0 QkekZ0 fMxzh çnku djus okys 66 d'yst gSaA mÙkj çns'k esa vusd çfrf"Br 'kks/k laLFkku gSa] tSls&
• lh,lvkbZvkj&dsaæh; vkS"kf/k vuqla/kku laLFkku ¼lhMhvkjvkbZ½] y[kuÅA
• lh,lvkbZvkj&Hkkjrh fo"kfoKku vuqla/kku laLFkku ¼vkbZvkbZVhvkj½] y[kuÅA
• lh,lvkbZvkj&dsaæh; vkS"k/kh; ,oa lxa/k ikS/kk laLFkku] y[kuÅA
• lh,lvkbZvkj&jk"Vªh; okuLifrd vuqla/kku laLFkku] y[kuÅA
• jk"Vªh; vkS"k/kh; f'k{kk ,oa vuqla/kku laLFkku ¼,uvkbZihbZvkj½] jk;cjsyhA
• tSfod foKku vkSj tSo vfHk;kaf=dh foHkkx] vkbZvkbZVh&dkuiqjA
• tSo çkS|ksfxdh foHkkx] ,e,u,uvkbZVh&ç;kxjktA
• Hkkjrh; çkS|ksfxdh laLFkku& cukjl fganw fo'ofo|ky; ¼vkbZvkbZVh] ch,p;w½ A
• fdax tktZ fpfdRlk fo'ofo|ky;] y[kuÅA
• lat; xka/kh iksLV xzstq,V baLVhVîwV v'Q esfMdy lkbalst] y[kuÅA
• Hkkjrh; Hks"kt lafgrk vk;ksx] xkft;kcknA
• jk"Vªh; tSfod laLFkku] uks,MkA
3-1-2& &
tSlk fd Hkkjrh; QkekZL;qfVdy m|ksx fu;kZrksUeq[k gSA mÙkj çns'k esa fu;kZr dks lqfo/kktud cukus okyk cqfu;knh
• Lof.kZe prqHkqZt ij fLFkr gSA
• mR—"V lM+d usVodZA
• if'pe esa jk"Vªh; jkt/kkuh {ks= rd igqapA
• iwohZ Hkkjr ds cktkj vkSj lalk/ku dh xgjkbZ rd j.kuhfrd igqapA
• 8]949 fdyksehVj esa QSyk ns'k dk lcls cM+k jsyos usVodZ gSA
• 'ks"k Hkkjr] e/; iwoZ ,oa nf{k.k iwoZ ,f'k;kbZ ns'kksa dks tksM+us okys çeq[k jk"Vªh; vkSj varjkZ"Vªh; gokbZ vM~Ms A
• y[kuÅ] dq'khuxj vkSj okjk.klh esa rhu fo|eku varjjk"Vªh; gokbZ vM~Ms rFkk vkus okys le; esa tsoj esa ,d vkSj varjjk"Vªh; gokbZ vM~Mk A
• ç;kxjkt dks gfYn;k canjxkg ls tksM+us okyk çLrkfor jk"Vªh; tyekxZ&1 ¼,uMCY;w&1½A • mRrj çns'k esa fnYyh&eqacbZ baMfLVª;y d'fjMksj ¼Mh,evkbZlh½ dk 8-5% dSpesaV ,fj;k vkSj ve`rlj&dksydkrk baMfLVª;y d'fjMksj ¼,dsvkbZlh½ dk 57%A
• xzsVj uks,Mk esa osLVuZ MsfMdsVsM ÝsV d'fjMksj ¼MCY;wMh,Qlh½ vkSj bZLVuZ MsfMdsVsM ÝsV d'fjMksj ¼bZMh,Qlh½ dk pkSjkgkA
• eYVh&eksMy y'ftfLVd gc] vkS|ksfxd ikdZ vkfn canjxkgksa rd de ;k=k le; ls ykHkkfUor gksaxsA
• iwokaZpy ,Dlçslos ¼340 fdyksehVj½] cqansy[kaM ,Dlçslos] y[kuÅ&vkxjk ,Dlçslos vkfn tSls ekStwnk vkSj gky gh esa fodflr ,Dlçslos( 4&ysu vkSj 6&ysu jkT; jktekxZ( jk"Vªh; vkSj varjkZ"Vªh; gokbZ vM~Ms( ç;kxjkt] okjk.klh vkSj gfYn;k leqæh canjxkg vkfn dks tksM+us okys ,uMCY;w&1 tyekxZ ls ok;q] ty] lM+d vkSj jsy usVodZ dk tky rS;kj gksus dh vk'kk gSA 4 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 • mRrj Hkkjr dk igyk fpfdRlk midj.k ikdZ ;equk ,Dlçslos vkS|ksfxd fodkl çkf/kdj.k ¼okbZbZvkbZMh,½ {ks= ds lsDVj 28 esa fodflr fd;k x;k gSA 3-2& &
• tsusfjd nokvksa lfgr cYd Mªx ,oa QkewZys'ku dk fuekZ.k
• vuqla/kku ,oa fodkl
• vkS"kf/k ijh{k.k rduhd
• vuqca/k vuqla/kku vkSj fofuekZ.k lsok,a ¼lh0vkj0,0,e0,l0½
• ck;ksy'ftDl vkSj ck;ksflfeyj
• vk;q"k vkSj QkbVksesfMflUl
• forj.k&829 O;fä çfr oxZ fdeh ds tula[;k ?kuRo ds lkFk mÙkj çns'k ns'k dk pkSFkk lcls cM+k jkT; gSA lHkh çdkj dh nokvksa ds forj.k ds fy, ,d forj.k ra= dks fodflr djus dh vR;Ur vko';drk gS A
• fpfdRlk midj.kksa dk fuekZ.k& u, vLirkyksa vkSj uflaZx gkse ds vkus vkSj ekStwnk lqfo/kkvksa ds iqu:)kj ds lkFk] mÙkj çns'k esa fpfdRlk midj.kksa dk fuekZ.k ,d vk'kktud volj gSA
4& &
4-1& &
QkekZL;qfVdy vkSj fpfdRlk midj.k m|ksx dks lkoZtfud LokLF; lsokvksa esa lq/kkj ds fy, fujarj vuqla/kku vkSj uokpkj dh vko';drk gSA
• QkewZys'ku] lfØ; QkekZL;qfVdy vo;o ¼,ihvkbZ½] çeq[k çkjafHkd lkexzh ¼ds,l,e½] Mªx baVjehfM,V~l ¼MhvkbZ½] bu foVªks Mk;XuksfLVDl ¼vkbZohMh½ vkSj d'LesfVDl lfgr fpfdRlk midj.kksa ds fuekZ.k ds fy, vk/kqfud QkekZL;qfVdy vkSj fpfdRlk midj.k ikdZ dh LFkkiuk dks c<+kok nsukA • vk/kqfud QkekZL;qfVdy vkSj fpfdRlk midj.k vuqla/kku dks çksRlkfgr djus ds fy,] fo'o Lrjh; cqfu;knh
• QkekZL;qfVdy {ks= esa vuqla/kku ,oa fodkl laLFkkuksa dks lqfo/kk çnku djds vkSj QkekZL;qfVdy {ks= esa vuqla/kku ,oa fodkl ds fy, vf/kd /kujkf'k dk ;ksxnku djds ckSf)d laink ¼vkbZih½ ds fuekZ.k dks c<+kok nsukA
• vuqla/kku ,oa fodkl dks c<+kok nsus vkSj vk;q"k LokLF; ns[kHkky mRiknksa ds fuekZ.k ds ek/;e ls vk;q"k LokLF; lsok dks c<+kok nsukA
4-2& &
• ;g uhfr] mÙkj çns'k QkekZL;qfVdy m|ksx uhfr] 2018 ds lekIr gksus ds fnukad ds i'pkr vFkkZr~ 08&06&2023 ls çHkkoh gksxh vkSj 05 o"kZ dh vof/k ds fy, ykxw jgsxhA
• ;fn fdlh Hkh Lrj ij ,slh fLFkfr mRiUu gksrh gS] ftlds dkj.k uhfr esa fdlh la'kks/ku ;k vf/kØe.k dh vko';drk gksrh gS] rks ,sls la'kks/kuksa@vf/kØe.k dks vuqeksfnr djus ds fy, dsoy ekå eaf= ifj"kn vf/k—r gksxhA
• bl uhfr esa fdlh Hkh la'kks/ku dh fLFkfr esa] ;fn jkT; ljdkj }kjk fdlh bdkbZ dks çksRlkgu dk dksbZ iSdst igys ls gh çfrc) gS] rks mls okil ugha fy;k tk,xk vkSj bdkbZ ykHk dh gdnkj cuh jgsxhA
4-3& &
¼1½ ≤≤ ij ;Fkk&la'kksf/kr Hkkjr ljdkj ds ,e,l,ebZMh vf/kfu;e] 2006 ds v/khu ;Fkk&vuqeksfnr iwath fuos'k okyh ifj;kstuk,¡A mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 5
¼2½ &,e,l,ebZ bdkb;ksa ls vf/kd fdUrq #i;s 100 djksM+ ls de iwath fuos'k okyh ifj;kstuk,aA
¼3½ &#i;s 100 djksM+ ls vf/kd iwath fuos'k okyh ifj;kstuk,aA
¼4½
&de ls de 05 bdkb;ksa ds lkFk U;wure 10 ,dM+ esa fodflr futh ikdZ] vkSj ftldk 60% m|fe;ksa dks vkoafVr fd;k x;k gksA
¼5½
&de ls de 03 bdkb;ksa ds lkFk U;wure 03 ,dM+ Hkwfe ij Vkoj ;k Vkojksa ds lewg dh rjg fodflr futh ikdZ] ftldk 60% m|fe;ksa dks vkoafVr fd;k x;k gks A
¼6½ &blesa ubZ vkS"kf/k fodflr djus ds fy, fd, x, dk;Z] u, Q'ewZys'ku] mRiknu dh ubZ rduhd] uohu Mªx Mhfyojh flLVe] Q'ewZys'ku dk fodkl] u, fpfdRlk midj.k dk fodkl lfEefyr gS A
¼7½
&fdlh vkS"kf/k ¼vkS"k/kh;½ mRikn ds fuekZ.k esa mi;ksx fd;k tkus okyk dksbZ Hkh inkFkZ ;k inkFkksaZ dk feJ.k tc vkS"kf/k ds mRiknu esa mi;ksx fd;k tkrk gS] rks vkS"kf/k mRikn dk ,d lfØ; ?kVd cu tkrk gSA bl rjg ds inkFkksaZ dk mís'; jksx ds funku] bykt] 'keu] mipkj ;k jksdFkke esa vkS"k/kh; xfrfof/k ;k vU; çR;{k çHkko çLrqr djuk ;k 'kjhj dh lajpuk ;k dk;Z dks çHkkfor djuk gSA
¼8½ &,d ,ihvkbZ ds la'ys"k.k esa e/;orhZ pj.kksa ds nkSjku mRikfnr lkexzh] ftls ,ihvkbZ cuus ls igys vkxs vk.kfod ifjorZu ;k çlaLdj.k ls xqtjuk gksxkA
¼9½ &,d dPpk eky] e/;orhZ ;k ,d ,ihvkbZ ftldk mi;ksx ,ihvkbZ ds mRiknu esa fd;k tkrk gS vkSj ftls ,ihvkbZ dh lajpuk esa ,d egRoiw.kZ lajpukRed [kaM ds :i esa 'kkfey fd;k tkrk gSA ds,l,e ,d O;kolkf;d lkexzh] vuqca/k ;k okf.kfT;d le>kSrs ds v/khu ,d ;k ,d ls vf/kd vkiwfrZdrkZvksa ls [kjhnh xbZ lkexzh ;k ?kjsyw mRikfnr lkexzh gks ldrk gSA ds,l,e vkerkSj ij ifjHkkf"kr jklk;fud xq.kksa vkSj lajpuk ds gksrs gSaA
5& &
5-1& &
5-1-1&
&çLrkfor uhfr QkekZ m|ksx dh LFkkiuk vkSj fodkl ds fy, xq.koÙkkiw.kZ cqfu;knh
;s ikdZ jsMh&Vw&;wt vk/kkjHkwr lqfo/kkvksa] tSls d'eu VsfLVax yscksjsVjh] Mk;XuksfLVd lsaVj] ikoj LVs'ku] dksYM LVksjst] d'eu QSflfyVh lsaVj] vif'k"V mipkj la;a= vkSj ^o'd Vw odZ^ vo/kkj.kk ij cuh vU; cqfu;knh lqfo/kkvksa ls ;qä gksaxsA jkT;] fodkldrkZvksa dks vkS"kf/k ,oa çlk/ku lkexzh vf/kfu;e vkSj le;≤ ij mlds v/khu cuk, x, fu;eksa ;k fdlh vU; çklafxd dkuwu ds v/khu fufnZ"V ekudksa ds vk/kkj ij ,ihvkbZ@Q'ewZys'ku ySc dh vko';drk dks iwjk djus okyh xq.koÙkk ijh{k.k lqfo/kkvksa ds fuekZ.k ds fy, çksRlkfgr djsxkA ;g uhfr jkT; esa l{ke çkf/kdkjh }kjk fof/kor çekf.kr@vuqeksfnr ç;ksx'kkykvksa dh LFkkiuk dks c<+kok nsrh gSA
5-1-2&
&bl uhfr ds ek/;e ls] jkT; varjjk"Vªh; cktkj esa oSf'od ekudksa ls Li/kkZ djus ds fy, fofuekZ.k fnXxt cukus ij tksj nsrk gSA ;s esxk ifj;kstuk,a vuq"kaxh] MkmuLVªhe vkSj ,l,ebZ bdkb;ksa ds fy, O;kid volj iSnk djrh gSaA blfy,] uhfr fo'ks"k çksRlkguksa vkSj fj;k;rksa ds ek/;e ls esxk ifj;kstukvksa dks vkdf"kZr djus dk çko/kku djrh gS] lkFk gh] rsth ls c<+rs {ks= esa voljksa dks çkIr djus ds fy, uhfr ,l,ebZ dk leFkZu djrh gSA bl uhfr ds v/khu {ks= esa ,l,ebZ bdkb;ksa ds fy, çksRlkgu vkSj fj;k;rksa ds fo'ks"k iSdst rS;kj fd, x, gSaA 6 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023
5-1-3& &
¼d½ &,ihvkbZ ,oa QkewZys'ku dk xq.koÙkk vk'oklu] QkekZL;qfVdy m|ksx ds es:n.M gSaA ,slh ç;ksx'kkyk,a vR;f/kd ykftfLVDl ,oa vk/kkjHkwr fuos'k ds lanHkZ esa pqukSfr;ksa dk lek/kku djrh gSaA ljdkj] çeq[k ljdkjh vuqla/kku laLFkkuksa vkSj vkS"kf/k ijh{k.k ç;ksx'kkykvksa ds ijke'kZ ls lkekU; ijh{k.k ç;ksx'kkyk ¼d'eu VsfLVax yScksjsVjh½ LFkkfir djus dh lqfo/kk çnku djsxhA
¼[k½ &rkieku laosnu'khy QkekZL;qfVdYl gsrq rkieku fu;af=r xksnke cukus ds fy, ljdkj m|ksxksa dks çksRlkfgr djsxhA bl uhfr ds v/khu lkekU; dksYM LVksjst lqfo/kkvksa ds fodkl dks çksRlkgu fn;k tk,xkA
5-2&
&
Lons'kh nokvksa dks c<+kok nsus ds fy, vk;q"k gsYFkds;j mRikn cukus okyh bdkb;ksa dks Hkwfe vkoaVu esa ojh;rk nh tk,xhA vk;q"k gsYFkds;j mRiknksa dk fuekZ.k djus okyh bdkb;ksa dks ikjaifjd Kku dh j{kk ds fy, fo'ks"k foi.ku çksRlkgu vkSj isVsaV Qkbfyax vkSj çek.ku çnku fd;k tk,xkA blh çdkj] oSdfYid nokvksa dks çksRlkfgr djus ds fy, jkT; QkbVksQkekZL;qfVdy vkS"kf/k;ksa dks c<+kok nsxk vkSj bu mRiknksa ds fy, cktkj fodflr djus ds fy, vuqla/kku vkSj mRiknu bdkb;ksa dks çksRlkgu çnku djsxkA 5-3& &
5-3-1&LokLF lsok ç.kkyh dh vko';drk dks iwjk djus ds fy, QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= ds fy, fujarj vuqla/kku] fodkl vkSj çkS|ksfxdh mUu;u dh vko';drk gSA QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= dh rkdr dkQh gn rd le; ds lkFk {ks= esa vuqla/kku ,oa fodkl dh çxfr ij fuHkZj djrh gSA mHkjrs oSf'od #>kuksa dks iwjk djus ds fy, QkekZ vkSj fpfdRlk midj.k {ks= ds lrr fodkl ds fy, uokpkj t:jh gSA mÙkj çns'k bl {ks= esa nqfu;k ds çfrf"Br vuqla/kku dsaæksa vkSj ekStwnk f'k{kk vkSj vuqla/kku vk/kkj dk ?kj gS] tks tSo&rduhd vkSj QkekZ ,oa fpfdRlk midj.k {ks= esa uokpkjksa ds fy, vikj Kku vkSj {kerk çnku djrk gSA
5-3-2&jkT dk mn~ns'; mRrj çns'k esa ekStwnk f'k{kk@vuqla/kku laLFkkuksa vkSj QkekZ daifu;ksa ds ek/;e ls fpfdRlk midj.k vkSj ,ihvkbZ ds çeq[k çkjafHkd lkexzh@Mªx baVjehfM,V lfgr ck;ks&Vsd vkSj QkekZ rFkk fpfdRlk midj.k esa vuqla/kku ,oa fodkl vkSj uokpkj ds fy, ykxr n{krk gsrq vuqla/kku çLrkoksa dks foÙkh; lgk;rk çnku djuk gSA
5-3-3&m|ksx] lh,lvkbZvkj vuqla/kku laLFkkuksa vkSj mRrj çns'k ds çeq[k vkS"kf/k vuqla/kku laLFkkuksa ds lg;ksx ls jkT;] vuqla/kku ifj;kstukvksa dks çk;ksftr djsxkA jkT;] vuqla/kku ifj;kstukvksa ds fy, dks"k cuk,xk vkSj lh,lvkbZvkj vuqla/kku ç;ksx'kkyk,a] vuqla/kku ifj;kstukvksa ds fy, jkT; dh Kku Hkkxhnkj gksaxhA bl uhfr dk mn~ns'; bl lanHkZ esa ,d etcwr m|ksx Qyd dk fuekZ.k djuk gSA m|ksx vkSj laLFkkuksa ds lg;ksx ls 'kq: dh xbZ vuqla/kku ifj;kstukvksa] uSnkfud ijh{k.k ifj;kstukvksa dks laj{k.k fn;k tk,xkA lkFk gh] isVsaV çkIr djus vkSj ckSf)d laink vf/kdkjksa dh j{kk djus esa ;g uhfr lgk;rk djsxhA
5-4& &
5-4-1&jkT] QkekZL;qfVdy vkSj fpfdRlk midj.k {ks= esa u, miØeksa ds ek/;e ls uokpkjksa dks çksRlkfgr djsxkA QkekZL;qfVdy ,oa fpfdRlk midj.k {ks= esa LVkVZ&vi dks c<+kok nsus ds fy,] jkT; le;≤ ij la'kksf/kr mÙkj çns'k LVkVZvi uhfr] 2020 ds v/khu LFkkfir mÙkj çns'k LVkVZ&vi QaM dk mi;ksx eq[; çkjafHkd lkexzh vkSj Mªx baVjehfM,V lfgr cYd Mªx@,ihvkbZ vkSj vkbZohMh lfgr fpfdRlk ;qfä;ksa vkSj çlk/ku lkexzh ds fuekZ.k dks c<+kus ds fy, djsxkA lh,lvkbZvkj vuqla/kku laLFkkuksa ,oa vuqHkoh is'ksojksa dh enn ls LVkVZ&vi bdkb;ksa dk p;u fd;k tk,xkA f'k{k.k laLFkkuksa] esfMdy d'ystksa vkSj fo'ofo|ky;ksa esa buD;wcsVj LFkkfir fd, tk,axsA ;g uhfr QkekZ vkSj fpfdRlk midj.k {ks= esa LVkVZvi dks muds O;olk; e'My dks c<+kus esa enn djus ds çko/kku djrh gSA mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 7
5-5& &
5-5-1& &mRrj çns'k ljdkj bl {ks= esa m|fe;ksa dh vko';drkvksa dks iwjk djus ds fy, xaHkhj ç;kl djsxhA uhfr u dsoy QkekZ vkSj fpfdRlk midj.k {ks= esa O;olk; LFkkfir djus ds fy, çksRlkfgr djrh gS cfYd fuos'kdksa dks vkdf"kZr djus ds fy, vuqdwy dkjksckjh okrkoj.k Hkh lqfuf'pr djrh gSA
5-5-2& &;g {ks= Kku vk/kkfjr gS vkSj jkT; esa m|ksx ds fodkl esa çfØ;kvksa dks vk—"V djus vkSj lqpk: cukus ds fy,] uhfr QkekZL;qfVdy m|ksx ds fy, flaxy foaMks Dyh;jsal lqfuf'pr djrh gSA uhfr mPp xq.koÙkk ekudksa vkSj vk/kqfud ijh{k.k lqfo/kkvksa dks lqfuf'pr djus ds fy, Hkh rRij gSA
5-5-3& &pwafd QkekZ m|ksx vif'k"V vkSj çokg dk mRiknu djrk gS] blfy, bl uhfr dk mís'; mRrj çns'k esa i;kZoj.k ds vuqdwy –f"Vdks.k ds lkFk QkekZ vkSj fpfdRlk midj.k {ks= dks c<+kok nsuk gSA vif'k"V mipkj vkSj i;kZoj.k laj{k.k ds fy, fo'ks"k çksRlkgu fn;k tk,xkA
6&
&
mRrj çns'k ljdkj] jkT; esa fo'ks"k :i ls bl {ks= ds fy, etcwr ikfjfLFkfrdh ra= okys {ks=ksa esa] QkekZL;qfVdy vkSj fpfdRlk midj.k ikdZ LFkkfir djus dh lqfo/kk çnku djsxhA ;s ikdZ ^Iyx&,aM&Iys^ vkS|ksfxd cqfu;knh
• fofuekZ.k {ks=(
• ijh{k.k {ks=(
• dksYM LVksjst vkSj os;jgkmflax(
• lkekU; lqfo/kk dsaæ] Nk=kokl {ks=(
• vU; lqfo/kk,a] tSls LVSaMvyksu ikoj LVs'ku] lhost VªhVesaV IykaV vkfnA ifjHkkf"kr {kSfrt vkSj Å/okZ/kj QkekZ ,oa fpfdRlk midj.k ikdZ ds fodkldrkZ bl uhfr ds v/khu çksRlkgu ds fy, ik= gksaxsA
6-1&çfr QkekZ vkSj fpfdRlk midj.k ikdZ çfr o"kZ 1-00 djksM+ #i;s dh vf/kdre lfClMh ds v/;/khu] Hkwfe [kjhnus gsrq fy, x, _.k ij okf"kZd C;kt ds 50% dh C;kt dh çfriwfrZ ds :i esa 07 o"kksaZ ds fy, C;kt lfClMhA
6-2&çR;sd QkekZ ,oa fpfdRlk midj.k ikdZ dks 50-00 djksM+ #i;s dh vf/kdre lfClMh ds v/;/khu çR;sd o"kZ 10-00 djksM+ #i;s rd QkekZ ,oa fpfdRlk midj.k ikdZ esa lM+dksa] fo|qr QhMj] ty fudklh vkfn tSls cqfu;knh
6-3&çR;sd QkekZ ,oa fpfdRlk midj.k ikdZ dks 30-00 djksM+ #i;s dh vf/kdre lfClMh ds v/;/khu çR;sd o"kZ 5-00 djksM+ #i;s rd QkekZ ,oa fpfdRlk midj.k ikdZ esa lkekU; lqfo/kk,a] tSls Hkk.Mkxkj ,oa dksYM psu lqfo/kk,a] Nk=kokl@M'jfeVªh] Jfedksa ds fy;s vkokl ds fuekZ.k gsrq fy;s x;s _.k ij 07 o"kksaZ ds fy;s okf"kZd C;kt ds 60 çfr'kr rd C;kt dh çfriwfrZ ds :i esa C;kt lfClMhA
6-4&fodkldrkZ }kjk Hkwfe dh [kjhn ij LV'Ei M~;wVh ij 100 çfr'kr dh NwV vkSj QkekZ ,oa fpfdRlk midj.k ikdZ esa O;fäxr [kjhnkjksa }kjk Hkw[k.M dh [kjhn ij çFke ckj LV'Ei M~;wVh ij 50 çfr'kr NwV çnku dh tk;sxhA
LV'Ei 'kqYd esa NwV] lerqY; jkf'k dh cSad xkj.Vh tek djus ij çnku dh tk;sxh] tks fodkldrkZ }kjk ikdZ fodflr gksus ds mijkUr voeqä dh tk;sxhA
6-5&futh QkekZL;qfVdy ikdksaZ esa lkekU; cqfu;knh 1116 RPH 2023 (Khadya Suraksha anubhag) data 1e 8 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 ik= lfClMh 05 o"kksaZ dh vof/k esa fd'rksa esa çnku dh tk,xh vkSj igyh fd'r okLrfod mRiknu 'kq: gksus ds ckn çnku dh tk,xhA
6-6&jkT] futh QkekZL;qfVdy ,oa fpfdRlk midj.k ikdZ fodflr djus ds fy, Hkwfe vf/kxzg.k dh lqfo/kk çnku djsxkA
7& &
QkekZL;qfVdy {ks= esa vkS|ksfxd fuos'k dks çksRlkfgr djus ds fy, jkT; ljdkj fj;k;rsa] lfClMh vkSj foÙkh; lgk;rk çnku djsxhA bl mís'; ds fy,] bl uhfr ds v/khu ik= ubZ QkekZL;qfVdy bdkb;ksa dks fuEufyf[kr çksRlkgu fn, tk,axs%&
7-1& &vf/kdre 1-00 djksM+ #i;s çfr o"kZ çfr ;wfuV dh lfClMh ds v/;/khu] la;a= vkSj e'khujh dh [kjhn gsrq fy, x, _.k ij çfriwfrZ ds :i esa 05 o"kksaZ ds fy, 5% çfr o"kZ dh nj ls C;kt lfClMhA
cqUnsy[k.M ,oa iwokaZpy ftyksa esa LFkkfir bdkb;ksa dks 02 çfr'kr okf"kZd dh nj ls vfrfjä C;kt lfClMh 07 o"kZ rd çfriwfrZ dh tk;sxhA
7-2& &jkT esa QkekZ ,oa fpfdRlk midj.k {ks= esa LFkkfir bdkb;ksa dks Lo&miksx gsrq volajpukRed lqfo/kkvksa] tSls lhost vkSj ty fudklh] fo|qr ykbu] VªkalQkeZj vkSj fo|qr QhMj dh LFkkiuk gsrq fy;s x;s _.k ij ns; C;kt dh jkf'k 05 çfr'kr dh nj ls vf/kdre 5 o"kZ dh vof/k rd] :0 1-00 djksM+ dh vf/kdre lfClMh ds v/;/khu] çfriwfrZ dh tk;sxhA
7-3& &:i;s 2-00 djksM+ #i;s dh lexz lhek ds v/;/khu] ijh{k.k ç;ksx'kkykvksa vkSj xq.koÙkk çek.ku ç;ksx'kkykvksa dks LFkkfir djus ds fy, la;a=] e'khujh vkSj midj.k dh [kjhn ij O;; djds vkS|ksfxd vuqla/kku] xq.koRrk lq/kkj vkSj mRiknksa ds fodkl gsrq fy, x, _.k ij çfriwfrZ ds :i esa 05 o"kksaZ ds fy, çfr o"kZ C;kt jkf'k dk 50% C;kt lfClMh A
7-4& &lHkh ubZ bdkb;ksa dks 10 o"kZ ds fy, 100% NwVA
7-5& &bl uhfr ds v/khu jkT; Hkj esa bdkbZ LFkkfir djus ds fy;s lHkh ubZ bdkb;ksa dks Hkwfe dh [kjhn vkSj Hkwfe@'ksM@Hkou ds iês ij 100% LVkEi 'kqYd esa NwVA
LV'Ei 'kqYd esa NwV] lerqY; jkf'k dh cSad xkj.Vh tek djus ij çnku dh tk;sxh] tks O;fäxr bdkbZ }kjk O;kolkf;d mRiknu çkjEHk gksus ds mijkUr voeqä dh tk;sxhA
7-6&vf/kdre 200 djksM+ #i;s dh lfClMh ds v/;/khu] bl uhfr ds v/khu la;a= vkSj e'khujh ds fuos'k ij iwathxr lfClMh çnku dh tk,xhA lfClMh dh jkf'k fuos'k ewY; dk 15% gksxhA
ik= lfClMh 05 o"kksaZ dh vof/k esa fd'rksa esa çnku dh tk,xh] vkSj igyh fd'r okLrfod mRiknu 'kq: gksus ds ckn çnku dh tk,xhA
7-7&futh QkekZL;qfVdy ikdksaZ esa LFkkfir bdkb;ksa dks vU; O;fäxr bdkb;ksa dh rjg çksRlkgu dk ykHk feysxkA
7-8&
&
7-8-1&cYd Mªx ikdZ@fpfdRlk midj.k ikdZ esa LFkkfir bdkb;ksa dks 10 o"kZ dh vof/k ds fy, C;kt lfClMh çnku dh tk,xhA
7-8-2
&ns'k ds Hkhrj vkSj ckgj dPps eky vkSj rS;kj eky ds ifjogu ds fy, le;≤ ij jkT; ljdkj }kjk r; dh xbZ nj ij ,;j dkxksZ gSaMfyax 'kqYd vkSj eky
7-9&
&
fo|eku bdkb;k¡] u, iwath fuos'k ds ek/;e ls de ls de 25% rd vius ldy Cy'd dks c<+k dj 25% mRiknu {kerk c<+k;s tkus ij] bl uhfr ds v/khu lHkh mu çksRlkguksa ds fy, ik= gksaxh] tks ubZ bdkbZ ij ykxw gksrs gSaA ldy Cy'd dka rkRi;Z bdkbZ ds orZeku fLFkj iw¡th fuos'k ls gSA
8& &
8-1&
&QkekZ vkSj fpfdRlk midj.k ikdksaZ ¼d'eu ,¶yq,aV VªhVesaV IykaV] balhujsVj vkfn½ esa 'kwU; vif'k"V@vif'k"V ty fudklh lqfo/kkvksa dks viukus gsrq d'eu ,¶yq,aV VªhVesaV IykaV] vif'k"V çcU/ku ç.kkyh dks yxkus ds fy;s fodkldrkZ] ifj;kstuk ykxr dk 40%] :i;s 10-00 djksM+ rd] vfrfjä i;kZoj.k laj{k.k baÝkLVªDpj lfClMh ds fy, ik= gksxkA Hkkjr ljdkj vkSj mÙkj çns'k ljdkj }kjk dqy leFkZu] bl ç;kstu ds fy, fd, x, dqy LFkk;h iwath fuos'k ds 75% ls vf/kd ugha gksxkA mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 9
8-2& &ubZ O;fDrxr QkekZ bdkb;ksa }kjk i;kZoj.k laj{k.k ds fy;s vko';d& okVj jhlkbfDyax] gkosZfLVax vkSj 'kwU; mRçokg rduhd viukus gsrq fy;s x;s _.k ds C;kt ij i;kZoj.k laj{k.k voLFkkiuk C;kt lfClMh ds #i esa 05 o"kZ rd 50 çfr'kr okf"kZd çfriwfrZ] vf/kdre :i;s 10-00 yk[k A
8-3& &de ls de nl ,e,l,ebZ }kjk viukbZ xbZ fLFkj LFkkiuk ykxr ds 35% ¼Bksl bZa/ku ds ekeys esa½ vkSj 50% ¼LoPN bZa/ku ds ekeys esa½ lfClMh ds fy, ik= gksaxh] tks :i;s 2-00 djksM+ rd gksxhA
i;kZoj.k laj{k.k lfClMh ds vUrxZr çfriwfrZ jkT; çnw"k.k fu;a=.k cksMZ ¼,l0ih0lh0ch0½] mÙkj çns'k }kjk fuxZr bl vk'k; dk çek.k&i= çLrqr djus ij nh tk,xhA
9& &
9-1&
&ckksVsd] vkbZohMh lfgr fpfdRlk midj.kksa vkSj QkekZ ,oa fpfdRlk midj.k {ks= esa vuqla/kku vkSj fodkl ds fy, LFkkfir u, vkj,aMMh laLFkkuksa dks e'khujh vkSj midj.k dh ifj;kstuk ykxr ds 30% rd vf/kdre 5-00 djksM+ #i;s rd dh lgk;rk çnku dh tk,xhA
9-2& &uhfr vof/k ds nkSjku ,d foRrh; o"kZ esa mÙkj çns'k ds Hkhrj fLFkr vuqla/kku ,oa fodkl laLFkku dks çfr uSnkfud ijh{k.k ij fd;s x;s dqy [kpZ dk 75 çfr'kr] vf/kdre :0 2-00 djksM+ dh çfriwfrZ A
9-3&vuqla/kku ,oa fodkl bdkbZ LFkkfir djus gsrq Hkwfe ,oa Hkou ds Ø;@[email protected] ds çFke ysu&nsu ij LVkEi 'kqYd esa 100 çfr'kr dh NwVA
LV'Ei 'kqYd esa NwV] lerqY; jkf'k dh cSad xkj.Vh tek djus ij çnku dh tk;sxh] tks vuqla/kku ,oa fodkl dk;Z çkjEHk gksus ds mijkUr voeqDr dh tk;sxhA
9-4&uhfr vof/k ds nkSjku mRrj çns'k ds Hkhrj fLFkr laLFkkuksa ds fy;s fdlh foRrh; o"kZ esa çfr ifj;kstuk vf/kdre :0 2-00 djksM+ ds v/;/khu] fdlh vkS|ksfxd bdkbZ@vkS|ksfxd laxBu }kjk mRrj çns'k esa fLFkr ljdkj@,0vkbZ0lh0Vh0bZ0 ls ekU;rk çkIr vuqla/kku ,oa fodkl laLFkku dks ck;ksVsd] QkekZL;qfVdy vkSj vkbZohMh lfgr fpfdRlk midj.k vuqla/kku ifj;kstuk çnku djus ij] vuqca/k@çk;ksftr vuqla/kku gsrq ifj;kstuk dh ykxr dk 50 çfr'kr] Hkwfe ,oa Hkou ykxr dks NksM+dj] lfClMh nh tk;sxhA
9-5&vuqca/k vuqla/kku laxBu bl uhfr ds v/khu O;fDrxr bdkb;ksa ds fy, ykxw çksRlkgu çkIr djus ds ik= gksaxsA
9-6& &
9-6-1&bdkbksa dks vius Jfedksa ds dkS'ky mUu;u gsrq ubZ rduhd@dkS'ky lh[kus ds fy, jk"Vªh; f'k{kqrk çksRlkgu ;kstuk ¼,u0,0ih0,l0½ vkSj eq[;ea=h f'k{kqrk çksRlkgu ;kstuk ¼lh0,e0,0ih0,l0½ ds v/khu ik= jkf'k ds cjkcj 6 ekg ds fy;s] çfr o"kZ vf/kdre 10 çf'k{kqvksa dks LVkbisaM fn;k tk,xkA
9-6-2&bdkbka ,u,ih,l@lh,e,ih,l iksVZy ij iathdj.k djds jk"Vªh; f'k{kqrk çksRlkgu ;kstuk ¼,u0,0ih0,l0½ vkSj eq[;ea=h f'k{kqrk çksRlkgu ;kstuk ¼lh0,e0,0ih0,l0½ ds v/khu QkesZlh Lukrd vkSj fMIyksek /kkjdksa dks çf'k{kq ds :i esa çf'k{k.k çnku djus ds fy, çksRlkgu dk ykHk mBk ldrh gSaA
10& &
10-1&çnRr isVs.V ij] ?kjsyw isVs.V ds fy, okLrfod isVs.V Qkbfyax ykxr dk 100% rd] vf/kdre :i;s 1-50 yk[k ds v/khu rFkk vUrjkZ"Vªh; isVs.V ds fy, isVs.V Qkbfyax ykxr dk 50% rd] vf/kdre :i;s 25-00 yk[k ds v/khu] isVs.V Qkbfyax 'kqYd dh çfriwfrZ dh tk;sxhA vk;q"k vkSj QkbVksesfMflu dk fuekZ.k djus okyh bdkb;ka uhfr vof/k esa çnRr isVs.V ij okLrfod isVs.V Qkbfyax ykxr dh iw.kZ çfriwfrZ ds fy, ik= gksaxhA
10-2& &bl uhfr vof/k ds nkSjku ;ksX; bdkb;ksa dks vkbZ,lvks çek.khdj.k ds fy;s ,d foRrh; o"kZ esa vkbZ,lvks çek.khdj.k O;; dk 75 çfr'kr( vf/kdre :i;s 75]000 çfr bdkbZ rFkk chvkbZ,l çek.khdj.k O;; dk 50 çfr'kr( vf/kdre :i;s 20]000 çfr bdkbZ çfriwfrZ dh tk;sxhA vk;q"k mRiknksa dk fuekZ.k djus okyh bdkb;k¡ xq.koRrk çek.ku ds fy;s O;; ykxr dh iw.kZ çfriwfrZ gsrq ik= gksaxhA 10 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023
10-3& &,ihvkbZ@QkewZys'ku ds fu;kZr ds fy, ;w,l,QMh,] MCY;w,pvks çh&DokfyfQds'ku] bZMhD;w,e] ,e,pvkj, ;k fdlh vU; varjkZ"Vªh; çek.ki=@vuqeksnu ds fy, fd, x, vkosnu O;; dk 50%] çfr ;wfuV vf/kdre 10 mRikn rd 25-00 yk[k #i;s çfr mRikn ds v/khu] dh çfriwfrZA
;g çksRlkgu de ls de 100 djksM+ #i;s ds okf.kfT;d fu;kZr ds lR;kiu ds ckn fn;k tk,xkA
11& &
&
ljdkj] jktdh; QkesZlh d'ystksa] laLFkkuksa@fo'ofo|ky;ksa vkSj ljdkjh vuqla/kku laLFkkuksa esa bUD;wcsVj LFkkfir djsxhA jkT; ljdkj futh {ks= ds lkFk lk>snkjh esa Hkh bUD;wcsVj LFkkfir djsxh A
11-1& &vf/kdre 1-00 djksM+ :i;s ds v/;/khu] ljdkjh estcku dh n'kk esa 75 çfr'kr rd vkSj vU; estcku dh n'kk esa 50 çfr'kr rd çfriwfrZ ds :i esa bUD;wcsVj dh LFkkiuk gsrq iw¡th vuqnku A
11-2& &05 o"kksaZ dh vof/k ds fy;s vf/kdre 10-00 yk[k #i;s rd çfr o"kZ ifjpkyu gsrq bUD;wcsVj }kjk ç;qä LFkku ij iV~Vk@fdjk;k 'kqYd ds 25 çfr'kr rd dh çfriwfrZA
11-3&çFke ysu&nsu gsrq Hkwfe ds foØ;@[email protected] vkSj dk;kZy; LFkku ij LV'Ei 'kqYd esa 100 çfr'kr dh NwVA
LV'Ei 'kqYd esa NwV] lerqY; jkf'k dh cSad xkj.Vh tek djus ij çnku dh tk;sxh] tks bUD;wcsVj }kjk okLrfod dk;Z çkjEHk fd;s tkus mijkUr voeqä dh tk;sxhA
11-4&05 o"kksaZ dh vof/k ds fy;s fo|qr dj esa 100 çfr'kr çfriwfrZA
11-5&es.Vjf'ki lgk;rk&uhfr dh vof/k ds nkSjku ,d ckj çR;sd es.Vj dks dksfpax] ekxZn'kZu] ;k=k] vLFkk;h vkokl vkfn ds gksus okys O;;ksa ls vkPNkfnr çfr es.Vj :i;s 2-00 yk[k dh es.Vjf'ki lgk;rkA
11-6&jkT] m|ksx dh vko';drk ds vuqlkj mÙkj çns'k ds fo'ofo|ky;ksa vkSj laLFkkuksa esa QkekZL;qfVdy vkSj fpfdRlk midj.k çkS|ksfxfd;ksa ds u, ikB~;Øe vkjEHk djus ds fy, çksRlkgu vkSj lqfo/kk çnku djsxkA
12& &
12-1 &QkekZ vkSj fpfdRlk midj.k {ks= dh ,e,l,ebZ bdkb;k¡ varjkZ"Vªh; çn'kZfu;ksa@esyksa esa çfrHkkx djus ds fy;s O;; dk 50 çfr'kr] ;k=k ,oa vkokl O;; dks NksM+dj] vf/kdre :i;s 5-00 yk[k] çfr bdkbZ O;; çfriwfrZ dh ik= gksaxhA ;g çksRlkgu] bdkbZ dks uhfr dh vof/k ds nkSjku o"kZ esa dsoy ,d ckj çnku fd;k tk,xkA
12-2&
&vkq"k ,oa QkbVksesfMflu dk fuekZ.k djus okyh bdkb;ksa dks ,d o"kZ esa varjjk"Vªh; çn'kZfu;ksa@esyksa esa çfrHkkx djus ds fy;s O;; dk 75 çfr'kr] ;k=k ,oa vkokl O;; dks NksM+dj( vf/kdre 05 yk[k #i;s çfr çn'kZuh@esyk çfriwfrZ rFkk Lons'kh çn'kZuh@esyksa esa çfrHkkx djus ds fy;s O;; dk 50 çfr'kr] ;k=k ,oa vkokl O;; dks NksM+dj( vf/kdre :i;s 2-00 yk[k çfr çn'kZuh@esyk çfriwfrZ dh tk;sxhA ;g çksRlkgu] bdkbZ dks lEiw.kZ uhfr vof/k ds nkSjku ,d ckj fn;k tk;sxkA %&
¼d½ QkekZ vkSj fpfdRlk midj.k ds {ks= esa çfriwfrZ] lfClMh] NwV vkfn ds :i esa leLr çksRlkgu ,e,l,ebZ] cM+h bdkb;ksa }kjk fd, x, fLFkj iwath fuos'k ds vf/kdre 100% ds v/;/khu gksaxsA
¼[k½ QkekZ vkSj fpfdRlk midj.k ds {ks= esa çfriwfrZ] lfClMh] NwV vkfn ds :i esa leLr çksRlkgu esxk bdkb;ksa }kjk fd, x, fLFkj iwath fuos'k ds vf/kdre 200% ds v/;/khu gksaxsA mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 11
13& &
jkT; dh mRrj çns'k vkS|ksfxd fuos'k vkSj jkstxkj çksRlkgu uhfr] 2022 ds –f"Vdks.k ,oa fe'ku dks vkxs c<+krs gq,] ;g uhfr Hkh O;olk; dks vklku cukus vkSj jkT; esa vuqdwy O;kolkf;d ifjos'k lqfu'pr djrh gSA
13-1 &bdkbksa dks lHkh visf{kr vuqeksnu jkT; dh ,dy f[kM+dh ç.kkyh ds ek/;e ls ,d gh Nr ds uhps çnku fd;s tk;saxs] ftldk vuqJo.k lh/ks eq[; ea=h dk;kZy; }kjk fd;k tk;sxkA
13-2& &Rofjr ,oa le;c) Loh—fr;k¡ çnku djuk bl uhfr dk çeq[k mís'; gSA bl mn~ns'; gsrq vf/kfu;e ds ek/;e ls lsokvksa] Loh—fr;ksa] vuqeksnuksa] ijfeVksa vkfn dk lle; çfriknu lqfuf'pr fd;k tk;sxk A
13-3& &[kk| lqj{kk ,oa vkS"kf/k ç'kklu ¼,Q,lMh,½ uksMy vf/kdkjh ukfer djsxk] tks QkekZL;qfVdy bdkb;ksa dh LFkkiuk ds fy, vko';d çnw"k.k ,uvkslh] Qk;j ,uvkslh vkSj vU; ,uvkslh@çek.ki=ksa dh eatwjh esa fuos'kdksa dh lgk;rk djsxkA
13-4
&fuos'kd ifj;kstuk vkSj Hkou ;kstuk dk Mksft;j çLrqr djsxk] ftldk ijh{k.k ifj;kstuk dh O;ogk;Zrk dk vkdyu djus ds fy, ,Q,lMh, Vhe }kjk dh tk,xhA Mksft;j dh lQy tkap ds ckn fuos'kd dks ysVj v'Q dEQVZ tkjh fd;k tk,xkA
13-5&dsaæ ljdkj dh ;kstuk ds v/khu Loh—r dksbZ Hkh cYd Mªx ikdZ@fpfdRlk midj.k ikdZ vkS|ksfxd fodkl foHkkx }kjk fodflr fd;k tk,xkA
,sls ikdksaZ esa bdkb;ksa ds fy, çksRlkgu] tks orZeku uhfr esa çnku fd, x, çksRlkgu ds vfrfjä gSa] dk fu/kkZj.k vkS|ksfxd fodkl foHkkx }kjk ekå eaf= ifj"kn ds lE;d~ vuqeksnu ds i'pkr fd;k tk,xkA
14& &
bl uhfr ds dk;kZUo;u vkSj vuqJo.k ds fy, [kk| lqj{kk ,oa vkS"kf/k ç'kklu foHkkx uksMy foHkkx gksxkA
14-1&mRrj çns'k QkekZL;qfVdy Msoyies.V lsy dks lykgdkj fudk; ds #i esa rduhdh ekxZn'kZu ,oa lgk;rk ds fy;s LFkkfir fd;k tk;sxkA vij eq[; lfpo@çeq[k lfpo] [kk| lqj{kk ,oa vkS"kf/k ç'kklu foHkkx }kjk lsy dh v/;{krk dh tk;sxh rFkk ftlesa lEcfU/kr foHkkxksa ds çfrfuf/k ,oa QkekZL;qfVdy vkSj tSo çkS|ksfxdh ds fofHkUu {ks=ksa ds fo'ks"kK lekfo"V gksaxsA m|ksx la?kksa ds çfrfuf/k vkeaf=r lnL; gksaxsA fu;ked lfefr;ksa vkSj vU; yksxksa }kjk fufnZ"V çdj.k le;≤ ij lsy }kjk fopkj fd;s tk;saxsA mRrj çns'k QkekZL;qfVdy Msoyies.V lsy fuEufyf[kr vf/kns'k ds lkFk dke djsxk&
¼,d½ jkT; esa QkekZL;qfVdy vkSj tSo çkS|ksfxdh ds lexz fodkl dks c<+kok nsuk] lgk;rk djuk vkSj lqxe cukukA
¼nks½ cqfu;knh
¼rhu½ QkekZL;qfVdy vkSj tSo çkS|ksfxdh dks c<+kok nsus ds fy;s {ks=h;] jk"Vªh; vkSj varjkZ"Vªh; usVofdaZx dks lqfo/kktud cukukA
¼pkj½ MkVk cSad vkSj lalk/ku dsaæksa ds fodkl dks lqfo/kktud cukukA
¼ik¡p½ oSKkfud tkx:drk] lkekftd&uSfrd Loh—fr] QkekZL;qfVdy vkSj tSo çkS|ksfxdh dks viukus ,oa vuqç;ksx dks lqfo/kktud cukukA
14-2&voLFkkiuk ,oa vkS|ksfxd fodkl vk;qä ds v/khu uhfr dk;kZUo;u bdkbZ ¼ihvkbZ;w½ dh LFkkiuk dh tk,xhA blds v/khu lw{e] y?kq ,oa e/;e m|eksa rFkk o`gr~ Jsf.k;ksa ds vkosnuksa dks vuqeksfnr fd;k tk;sxkA mRrj çns'k QkekZL;qfVdy MsoyiesaV lsy ds lkeUtL; ls bl uhfr ds v/khu ifjHkkf"kr bdkb;ksa ds fy, ykxw çksRlkguksa ds fufeÙk laLrqfr;ksa vkSj vuqeksnu çnku djus gsrq ihvkbZ;w mRrjnk;h gksxh vkSj le; ls f'kdk;rksa dk fuiVkjk djsxhA uhfr dk;kZUo;u bdkbZ esa voLFkkiuk ,oa vkS|ksfxd fodkl foHkkx] foKku ,oa çkS|ksfxdh foHkkx] [kk| lqj{kk ,oa vkS"kf/k ç'kklu foHkkx ,oa vk;q"k foHkkx ds vij eq[; lfpo@çeq[k lfpo@lfpo ¼;FkkfLFkfr½ lfEefyr gksaxsA 12 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 14-3&eq[; lfpo dh v/;{krk esa çkf/k—r lfefr mRrj çns'k QkekZL;qfVdy ,oa fpfdRlk midj.k m|ksx uhfr] 2023 ds fodkl dh ns[k&js[k vkSj blds dk;kZUo;u dk vuqJo.k djsxhA blds v/khu esxk Js.kh ds vkosnuksa dks vuqeksfnr fd;k tk;sxkA fofHkUu foHkkxksa ds vij eq[; lfpo@çeq[k lfpo@lfpo blds lnL; gksaxsA [kk| lqj{kk ,oa vkS"kf/k ç'kklu foHkkx ds vij eq[; lfpo@çeq[k lfpo@lfpo ¼;FkkfLFkfr½ lfefr ds leUo;d lfpo gksaxsA m|ksx la?kksa ds çfrfuf/k vkeaf=r lnL; gksaxsA
14-4&bl uhfr ds v/khu [kk| lqj{kk ,oa vkS"kf/k ç'kklu foHkkx uhfr ds dk;kZUo;u gsrq çkIr vkosnu@çLrko ds fuLrkj.k@lR;kiu dh çfØ;k ds fy, fdlh Hkh ,d ;k ,d ls vf/kd fo'ks"kK ,tsalh] tSls&fidi ¼ihvkbZlh;wih½] ;wihlhMk ¼;wih,lvkbZMh,½ vFkok oká ,tsalh vkfn dks lgc) dj ldrk gSA
vkKk ls]
vuhrk flag]
vij eq[; lfpoA
&&&&&&
UTTAR PRADESH PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRY
POLICY, 2023
1. Introduction –
The policy aims to revamp the state's pharmaceutical and medical device industry by encouraging local production, promoting research and development and improving the availability of affordable medicines to the citizens. The policy focuses on creating a conducive environment for the growth of the pharmaceutical industry in the state aiming to attract investments in the sector by providing a range of incentives such as subsidies and land allocation for setting up manufacturing units. The policy also intends to create a robust ecosystem for research and development by setting up state-of-the-art facilities and collaborating with academic institutions and research institutes.
The pharmaceutical and medical device sector in Uttar Pradesh has been gaining momentum in recent years and has been identified as a focus sector in the state's industrial policy. The Global Investor Summit, held in February 2023, further highlighted the potential of the sector and attracted significant investment. In response to the state government's efforts, 217 companies have proposed to invest nearly INR 28,500 crores in the pharmaceutical and medical devices sector. These investments are expected to create nearly 57000 job opportunities, boost the local economy, and contribute to the growth of the sector.
Pharmaceutical and medical device sector requires special technology, quality control system and hence special ecosystem is required to set up pharmaceutical and medical device industry.
2. India Scenario –
The Indian pharmaceutical industry is robust and thriving and is currently valued at USD 41.7 billion. India's domestic pharmaceutical market stood at USD 42 billion in 2021 and is likely to reach USD 65 billion by 2024 and further expand to USD 120 billion by 2030. The Indian pharmaceutical market ranks 3rd in terms of pharmaceutical production by volume and 14th by value, The industry includes a network of 3,000 pharmaceutical companies and 10,500 manufacturing units. India has the second highest number of USFDA approved facilities. In terms of overall revenue, the market increased by 13.9% in January 2022. India exports 20% of global generics, making it the largest provider of generic medicines globally. The country is the 12th largest exporter of medical goods in the world. Indian drug and pharmaceutical exports stood at USD 24.60 billion in FY22 and USD 24.44 billion in FY21.India is one of the top 20 global medical device markets and the 4th largest medical device market in Asia.
Major segments of the Indian pharmaceutical industry are generic drugs, OTC medicines, API/bulk drugs, vaccines, contract research and manufacturing, biosimilars and biologics. Pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan and Australia.
mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 13India offers up to 100% FDI through an automatic route for Greenfield pharmaceutical projects.
For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. Cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is USD 19,405.35 Million during the period April, 2000 to March, 2022.
The sector is also supported by Production Linked Incentive (PLI) Scheme to boost domestic manufacturing capacity of pharmaceutical and medical device. The financial outlay of the scheme is INR 25,360 crore. Products covered under the scheme are,–
Category-1:–Biopharmaceuticals, Complex generic drugs, Patented drugs or drugs nearing patent expiry, Cell-based or gene therapy products, Orphan drugs, Special empty capsules, Complex excipients, Phyto-pharmaceuticals.
Category-2:–Active Pharma Ingredients (APIs), Key Starting Materials (KSMs), Drug Intermediaries (DIS)
Category-3:–Repurposed Drugs, Auto-immune drugs, Anti-cancer drugs, Anti-diabetic drugs, Anti Infective drugs, Cardiovascular drugs, Psychotropic drugs, Anti-Retroviral drugs, Fermentation based 4 KSMS/DIS.
3. Advantage Uttar Pradesh –
Uttar Pradesh, with a viable ecosystem and a population of over 240 million, is India's third largest economy and largest consumer market. With the highest population among all Indian states, Uttar Pradesh offers to be the biggest market for pharmaceuticals. With increase in the middle class population most of the people can afford quality healthcare, thereby creating higher demand for pharmaceutical sector.
The State has a 3-tier public healthcare infrastructure, comprising community health centres (CHCs), primary health centres (PHCs) and sub-centres. UP is amongst the top five manufacturing states of India and has the second highest number of Micro, Small and Medium Enterprises in India.
Uttar Pradesh has strong distribution networks for healthcare products and medicines with 71880 wholesale drug sale licence and 108927 retail drug sale licence. There are 619 manufacturing units which included allopathic, homoeopathic, medical devices and cosmetics units; and 485 blood banks in the state to serve need of whole human blood and blood components. There is huge scope for setting up new units in the state.
3.1. Enabling Ecosystem-
3.1.1. Availability of Manpower and Strong R and D base-
The State has perennial supply of manpower and prestigious research institutes and Department of Pharmaceutics in various educational institutes. The Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh has 401 colleges providing B.Pharm degree and 66 colleges providing M.Pharm degree. Uttar Pradesh has prestigious research institutes like-
• CSIR-Central Drug Research Institute (CDRI), Lucknow.
• CSIR-Indian Institute of Toxicology Research (IITR), Lucknow.
• CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow.
• CSIR-National Botanical Research Institute, Lucknow.
• National Institute of Pharmaceutical Education and Research (NIPER), Raebareli.
• Biological Sciences and Bioengineering Department, IIT- Kanpur.
• Biotechnology Department, MNNIT- Prayagraj.
• Indian Institute of Technology-Banaras Hindu University (IIT-BHU).
• King George's Medical University, Lucknow.
• Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow.
• Indian Pharmacopoeia Commission, Ghaziabad.
• National Institute of Biologicals, Noida.
14 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 20233.1.2. Infrastructure Advantage–
As the Indian pharmaceutical industry is export-orientated. Uttar Pradesh has suitable export facilitating infrastructure:–
• Located on Golden Quadrilateral.
• Excellent road network.
• Access to National Capital Region on the west.
• Strategic access to market & resource depth of eastern India.
• Largest railway network in the country spanning over 8,949 km.
• Major national & international airports connecting the rest of India, Middle East & South East Asian countries.
• Three existing international airports at Lucknow, Kushinagar and Varanasi, and one upcoming international airport Jewar.
• Proposed National Waterway-1 (NW-1) connecting Prayagraj to Haldia port.
• 8.5% of Delhi Mumbai Industrial Corridor (DMIC) catchment area and 57% of Amritsar-Kolkata Industrial Corridor (AKIC) in UP.
• Intersection of Western Dedicated Freight Corridor (WDFC) and Eastern Dedicated Freight Corridor (EDFC) at Greater Noida.
• Multi-modal logistic hubs, industrial parks etc. to benefit from reduced travel time to ports.
• Existing and recently developed expressways like Purvanchal Expressway (340-km), Bundelkhand Expressway, Lucknow-Agra Expressway etc.; 4-lane and 6-lane state highways; national and international airports; NW 1 waterways connecting Prayagraj, Varanasi and Haldia sea port etc., is expected to create a web of air, water, road and rail network.
• Northern India's first Medical Device Park is developed in Sector 28 of the Yamuna Expressway Industrial Development Authority (YEIDA) Space.
3.2. Opportunities in Uttar Pradesh –
• Manufacturing Bulk Drugs and Formulations including Generic Medicines
• Research and Development
o Drug Testing Technology
o Contract Research and Manufacturing Services (CRAMS)
o Biologics and Biosimilars
o AYUSH and Phytomedicine
• Distribution Uttar Pradesh is the 4th largest state with population density of 829 people per sq.km. There is immense scope for development of a mechanism for distribution of all kinds of drugs.
• Manufacturing Medical Devices- With new hospitals and nursing houses coming up and renovation of existing facilities, manufacturing medical devices in Uttar Pradesh is a promising opportunity.
4. About Policy –
4.1. Objectives-
Pharmaceutical and Medical Device Industry needs continuous research and innovation to improve public health services.
• To promote establishment of modern Pharmaceutical and Medical Device Parks for manufacturing of Formulations, Active Pharmaceutical Ingredients (API), Key Starting Material (KSM), Drug Intermediates (DI), Medical Devices including In Vitro Diagnostics (IVD) and Cosmetics.
• To encourage modern pharmaceutical and medical device research, build world class infrastructure and attract world's best talent to contribute to the State's development.
mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 15• To promote creation of intellectual property (IP) in the pharmaceutical sector by facilitating R&D institutions and contributing more funds to R and D in the pharmaceutical sector.
• To promote AYUSH healthcare through promotion of R and D and manufacturing of AYUSH healthcare products.
4.2. Period of the policy–
• This policy will be effective after the date of expiry of Uttar Pradesh Pharmaceutical Industry Policy, 2018, i.e., 08-06-2023 and will remain in force for the period of 5 years.
• If at any stage a situation arises which necessitates any amendment or supersession of the policy, only the cabinet will be authorised to approve such amendments/supersession.
• In case of any amendment in this policy, if any package of incentives is already committed by the state government to any unit, will not be withdrawn and the unit will continue to remain entitled to the benefits.
4.3. Definitions –
1. M.S.M.E. Units- Projects with capital investment as approved under Govt. of India's MSMED Act, 2006 as amended from time to time.
2. Large Units- Projects with capital investment over that of MSME units but less than INR 100 crores.
3. Mega Units-Projects with capital investment of more than INR 100 crores.
4. Horizontal Pharma and Medical Device Park-Private parks developed over minimum 10 acres, with at least 05 units, and 60% of which is allotted to entrepreneurs.
5. Vertical Pharma and Medical Device Park-Private parks developed like a tower or group of towers on minimum area 03 acres of land, with at least 03 units, and 60% of which is allotted to entrepreneurs.
6. Research and Development-Includes work done in order to develop new drug, new formulation, novel technology of production, novel drug delivery system, development of formulation, development of new medical device.
7. Active Pharmaceutical Ingredient (API)-Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or function of the body.
8. Drug Intermediate (DI)-A material produced during intermediate steps in the synthesis of an API that must undergo further molecular change or processing before it becomes an API.
9. Key Starting Material (KSM)-A raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. KSM can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. KSMs are normally of defined chemical properties and structure.
KSM, DI and API identified by Government of India and Drug Controller General (India) from time to time shall be eligible for this policy.
5. Policy Framework –
5.1. Developing Infrastructure -
5.1.1. Focus on Pharma and Medical Device Park-The policy will facilitate quality infrastructure and support base for establishment and growth of pharma industry in UP. The policy intends to identify land parcels and develop Parks, for manufacturing allopathic, AYUSH products, Medical devices, and Key Starting Materials/Drug Intermediates used in Bulk drug manufacturing. These parks will be equipped with ready-to-use infrastructural facilities such as common testing laboratories, diagnostic centres, power station, cold storages, common facility centres, effluent treatment plants and other basic amenities built on 'walk to 16 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 work' concept. The State will encourage the developers to build quality testing facilities meeting requirement of API/Formulation Lab and standards as specified under Drugs and Cosmetics Act and Rules made there under from time to time or any other relevant law. The policy promotes setting up of labs duly certified/approved by Competent Authority in the state.
5.1.2. Focus on Mega Projects and SMEs-Through this policy, the state puts high impetus on creating manufacturing giants to compete global standards in international market.
These mega projects create wide opportunities for ancillaries, downstream and SME units.
Therefore, the policy provides to attract Mega projects through special incentives and concessions, while also, the policy support the SMEs to grab the opportunities in the booming sector. Special packages of incentives and concessions have been designed for SMEs units in the sector under this policy.
5.1.3. Supporting Infrastructure –
(A) API/Formulation Lab-Quality assurance of API and Formulation is back bone of Pharmaceutical Industry. Such a lab would resolve the challenges such as excessive logistics and infrastructure investment. Government will facilitate to setup Common Testing Laboratory with consultation of premier government research institutes and drug testing laboratories. This facility will enhance the presence of research and development activity in the value chain.
(B) Cold Storage facilities-Government will encourage industries in creating a temperature controlled warehouse for temperature sensitive pharmaceuticals. Development of common cold storage facilities will be incentivised under this policy.
5.2. Promoting AYUSH and Phytomedicine –
In order to promote indigenous medicine, Units manufacturing AYUSH healthcare products will be given preference in land allotment. In order to safeguard the traditional knowledge special marketing incentives and for patent filing and certification will be provided to units manufacturing Ayush healthcare products. Similarly, the State will promote Phytopharmaceutical Drugs to encourage alternative medicine and will provide incentives to research and production units to develop market for these products.
5.3. Research and Development –
5.3.1. Continuous research, development and technology upgradation are need of the pharmaceutical and medical device sector to meet requirement of healthcare system. The strength of pharmaceutical and medical device sector largely depends on advancement of R&D in the sector over the time. Innovation is must for sustained development of the pharma and medical device sector to meet emerging global trends. Uttar Pradesh is home to world's reputed research centres in the sector, and existing education & research base, which provides immense knowledge and have potential for innovations in bio-tech and Pharma and Medical Device Sector.
5.3.2. The State aims at providing financial support to the research proposals for R&D and innovation in bio-tech and Pharma and Medical Device Sector including medical device and Key Starting Material/Drug Intermediates of API, through the existing education/research institutes and pharma companies in Uttar Pradesh to drive cost efficiencies.
5.3.3. State will sponsor research projects in collaboration with Industry, CSIR research institutes and premier pharmaceutical research institutes of Uttar Pradesh. State will create fund for research projects and CSIR research laboratories will be knowledge partners of the state for research projects. The policy aims at building a strong industry interface in this context. Research projects, clinical trial projects taken up in collaboration with Industry and Institutions will be patronized. Also, the policy will assist in acquiring Patent, and protecting Intellectual Property Rights.
mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 175.4. Promoting Innovations and Start up –
5.4.1. State will encourage innovations through new ventures in Pharmaceutical and medical device sector. In order to promote Start-ups in pharmaceutical and medical device sector, the state will use Uttar Pradesh Start-up Fund set up under Uttar Pradesh Start-up Policy, 2020, as amended from time to time, to scale up manufacturing of Bulk Drug/API, Key Starting Material, Drug Intermediates, Medical Devices including IVD and Cosmetics.
Start-up units will be selected with the help of CSIR research institutes and experience professionals. Incubators at educational institutions, medical colleges and universities would be set up. The policy provides provisions to help Start-ups in Pharma and Medical Device Sector to scale up their business models.
5.5. Ecosystem Support –
5.5.1. Conducive Business Environment-Government of Uttar Pradesh will make sincere efforts to meet requirements of entrepreneurs in the sector. The policy not only incentivises setting up business in Pharma and medical device sector but also ensures a conducive business environment to attract investors.
5.5.2. Simplified Procedures-The sector is knowledge based and in order to attract and smoothern processes in development of the industry in state, the policy ensures single window clearances to Pharmaceutical Industry. The policy also looks forward to ensuring high quality standards and modern testing facilities.
5.5.3. Eco friendly approach-Since pharma industry produces waste and effluent, this policy aims at promoting the pharma and medical device sector in Uttar Pradesh with an eco- friendly approach. Special incentives will be given for effluent treatment and environment protection.
6. Private Pharmaceutical and Medical Device Parks –
Government of Uttar Pradesh will facilitate setting up Pharmaceutical and Medical Device Parks in the state, especially in areas with strong ecosystem support for the sector. These parks will provide 'plug-and-play' industrial infrastructure allowing companies to focus on their core business, and therefore will comprise–
• Manufacturing area;
• Testing area;
• Cold storages and warehousing;
• Common facility centres, hostel areas;
• Other facilities such as standalone power station, sewage treatment plant, etc.
The developers of defined Horizontal and Vertical Pharma and Medical Device park shall be eligible for incentives under this policy -
6.1. Interest subsidy in the form of reimbursement of interest of 50% of annual interest on the loan taken to buy land for 07 years subject to a maximum subsidy of INR 1.00 crore per annum per Pharma and Medical Device Park.
6.2. Interest subsidy in the form of reimbursement of interest of 60% of annual interest for 07 years on the loan taken for building infrastructure such as roads, power feeder, drainage in the pharma and medical device park up to INR 10.00 crores per year, subject to maximum subsidy of INR 50.00 crores per Pharma and Medical Device Park.
6.3. Interest subsidy in the form of reimbursement of interest of 60% of annual interest for 07 years on the loan taken for building common facilities warehouse & cold chain facilities, Hostel/Dormitory, Housing for workers in the Pharma and Medical Device Parks up to INR 5.00 crores per year, subject to maximum subsidy of INR 30.00 crores per Pharma and Medical Device Park.
6.4. 100% exemption on stamp duty on the purchase of land by the developer and 50% exemption on stamp duty to individual buyers of first instance will be provided on purchase of plot in the Pharma and Medical Device Parks.
18 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023The stamp duty exemption will be provided on submission of bank guarantee of equivalent amount which will be released on completion of development of the park by the developer.
6.5. Capital subsidy to develop common infrastructure and utilities in Private Pharmaceutical Parks will be 15% of the investment value. This subsidy will be provided for development of common infrastructure and utilities, like- cold storage, warehouse, common testing facilities subject to a maximum limit of INR 25.00 crores. Capital subsidy will not be provided on the investment of roads, parks, drainage systém.
The eligible subsidy will be provided in instalments over a period of 05 years and first instalment will be provided after commencement of actual production.
6.6. State will facilitate land acquisition to develop Private Pharmaceutical and Medical Device Parks.
7. Incentives to units –
In order to encourage industrial investment in the pharmaceutical sector, the State Government will provide concessions, subsidies and financial assistance.For this purpose, following incentives will be extended to eligible new pharmaceutical units under this policy :–
7.1. Capital interest subsidy-Interest subsidy at rate of 5% per annum for 05 years in the form of reimbursement on loan taken for procurement of plant & machinery, subject to maximum subsidy of INR 1.00 Crore per annum per unit.
Additional interest subsidy at rate of 2% per annum for 07 years will be reimbursed to the units established in Bundelkhand and Purvanchal Districts.
7.2. Infrastructure Interest Subsidy-Units setup in Pharma and Medical Device Sector in the state, will for a maximum period of 05 years be reimbursed the amount of interest at the rate of 5% payable on loan taken by them for developing infrastructural amenities for self-use like sewage and water drainage, erection of power line, transformer and power feeder, subject to maximum subsidy of INR 1.00 crore.
7.3. Industry Research Subsidy-Interest subsidy of 50% of interest amount per annum for 05 years in the form of reimbursement on loan taken for industrial research, quality improvement and development of products by incurring expenditure on procurement of plant, machinery & equipment for setting up testing labs and quality certification labs, subject to an overall ceiling of Rs 2.00 Crores.
7.4. Electricity duty exemption-100% exemption for 10 years to all new units.
7.5. Stamp Duty Incentive-100% Stamp duty exemption to all new units across the state on purchase of land and lease of land/shed/building to establish units under this policy.
The stamp duty exemption will be provided on submission of bank guarantee of equivalent amount which will be released on commercial production by individual unit.
7.6. Capital Subsidy on the investment of plant and machinery will be provided under this policy. The amount of subsidy will be 15% of the investment value, subject to maximum subsidy of INR 200 Crores. The eligible subsidy will be provided in the instalments over the period of 05 years, and first instalment will be provided after commencement of actual production.
7.7. Units established in Private Pharmaceutical Parks will get same benefits of incentives as other individual units.
7.8. Special package for Bulk Drug Parks and Medical Device Parks-
7.8.1. The interest subsidy will be provided for the period of 10 years to the units established in Bulk Drug Parks/Medical Device Parks.
7.8.2. Air Cargo Handling Charges and Freight Incentives-Special incentives for air cargo handling charges and freight charges will be provided at the rate decided by State Government from time to time to transport raw material and finished goods in and out of the country.
mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 197.9. Incentive for expansion of existing Units –
Existing units shall be eligible for all incentives under this policy as applicable to new unit where an existing enterprise increases its gross block by at least 25% and increase the production capacity by 25% through new capital investment.
Gross block refers to current fixed capital investment of the unit.
8. Environment Protection Subsidy –
8.1. Setting up Common Purpose ETPs-For adopting zero effluent /waste water discharge facilities at Pharma and Medical Device Parks (Common Effluent Treatment Plant, Incinerator etc.), developer will be eligible for additional environment protection infrastructure subsidy 40% of project cost to set up Common Effluent Treatment Plant, Waste Management System up INR 10.00 Crore. Total support by Government of India and Uttar Pradesh Government shall not exceed 75% of the total fixed capital investment incurred in this purpose.
8.2. Zero Waste Incentive-New individual pharma units eligible under this policy, adopting water recycling/harvesting and zero discharge technology shall be eligible for environment protection infrastructure interest subsidy on loan taken to set up such infrastructure to the extent of 50% of annual interest for 05 years; ceiling INR 10.00 lacs.
8.3. Common Boiler Project-Adopted by at least ten MSME will be eligible for the subsidy of 35% (in case of solid fuel) and 50% (in case of clean fuel) of the fixed installation cost, up to INR 2.00 Crores.
Reimbursement under Environment Protection Subsidy shall be made on producing a certificate from State Pollution Control Board (S.P.C.B.), Uttar Pradesh to this effect.
9. Research and Development Support –
9.1. Support Research and Development Institutes-New R&D institutes set up for research & development in biotech, medical devices including IVD and Pharma and Medical Device Sector, will be provided assistance up to 30% of the project cost of machinery and equipment maximum up to INR 5.00 crore.
9.2. Clinical Trials-75% reimbursement of the total expenditure incurred subject to maximum INR 2.00 crores per clinical trial to R&D institutes, situated within Uttar Pradesh, in a financial year over the policy period.
9.3. 100% exemption of Stamp duty on purchase/lease/transfer of land and building to establish research and development unit for first transaction.
The stamp duty exemption will be provided on submission of bank guarantee of equivalent amount which will be released on commencement of research and development work.
9.4. Assistance for contract/sponsored research work-For biotech, pharmaceutical and medical device including IVD research projects from any industrial unit/industry association to recognized R&D institution in Uttar Pradesh approved by Government/AICTE will be considered subsidy of 50% of the eligible project cost, excluding cost of land and building, subject to a maximum of INR 2.00 Crores per project in a financial year to institutes situated within Uttar Pradesh over the policy period.
9.5. Contract Research Organisation shall be eligible to avail incentives applicable to individual units under this policy.
9.6. Skill Development –
9.6.1. Stipend equivalent to the amount eligible under National Apprenticeship Promotion Scheme (NAPS) and Chief Minister Apprenticeship Promotion Scheme (CMAPS) will be given to the units in order to provide skill upgradation of their workers to learn new technology/skill for six months, up to maximum 10 trainees per annum.
9.6.2. Units can also avail incentive to impart training to Pharmacy graduates and diploma holders as apprentice under National Apprenticeship Promotion Scheme (NAPS) and Chief Minister Apprenticeship Promotion Scheme (CMAPS) by registering on NAPS/CMAPS portal.
20 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 202310. Patent Filing and Quality Certification –
10.1. Patent Filing fees will be reimbursed up to 100% of actual filing costs on awarded patents subject to a maximum of INR 1.50 lacs for domestic patents, and up to 50% of actual filing costs on awarded patents, subject to maximum of INR 25.00 Lacs for international patents.
Units manufacturing AYUSH and Phytomedicine will be eligible for full reimbursement of actual patent filing costs on awarded patents over the policy period.
10.2. Quality certification-Reimbursement of 75% of cost incurred for ISO certification subject to maximum INR 75,000 per unit in a financial year, and 50% of cost incurred for BIS certification, subject to maximum INR 20,000 per unit in a financial year. Units manufacturing AYUSH products will be eligible for full reimbursement towards cost incurred for quality certification over the period of this policy.
10.3. Certification/Approval for Export-Reimbursement of 50% of application fee incurred for certification/approval of USFDA, WHO Pre- Qualification, EDQM, MHRA or any other International Certificate/ approval for export of API/Formulation subject to maximum subsidy of INR. 25 lacs per product up to 10 products per unit. This incentive will be given after verification of commercial export of at least INR 100 Crores.
11. Innovations and Start Up –
Pharmaceutical Incubators-
Government will set up Incubators in Government Pharmacy Colleges, Institutes/Universities and Government Research Institutes. The State Government will also set up Incubators in partnership with private sector.
11.1. Capital Grants-for setting an incubator in form of reimbursement up to 75% in case of Govt. hosts, and up to 50% in case of other hosts, subject to maximum INR 1.00 crore.
11.2. Rebate on lease/Rental Space-Reimbursement.up to 25% of lease/rental charges on the space used by incubator for operations up to maximum INR 10.00 lacs per year, for a period of 05 years.
11.3. 100% exemption of Stamp duty on sale/lease/ transfer of land and office space for first transaction.
The stamp duty exemption will be provided on submission of bank guarantee of equivalent amount which will be released on commencement of actual work by incubator.
11.4. 100% reimbursement of electricity duty for a period of 05 years.
11.5. Mentorship Assistance of INR 2.00 lacs per mentor shall be provided, covering expenses incurred on coaching, guiding, travelling, lodging etc., one time over the Policy Period.
11.6. State will encourage and facilitate to start new courses of pharmaceutical and medical device technologies in the Universities and Institutes of Uttar Pradesh as per need of the industry.
12. Marketing Support –
12.1. MSME units-MSMEs in Pharma and Medical Device Sector will be eligible for reimbursement of 50% of cost of participation in international exhibitions/fairs, excluding travel and accommodation cost with a maximum amount of INR 5 lacs per unit. The incentive will be provided to a unit only once in a year over the policy period.
12.2. Market for AYUSH and Phytomedicine-Units manufacturing AYUSH or Phytomedicine shall be reimbursed 75% of cost of participation in international exhibitions/fairs excluding travel and accommodation subject to maximum INR 5.00 lacs per event in a year, and will be reimbursed 50% of cost of participation in domestic exhibitions/fairs excluding travel and accommodation subject to maximum INR 2.00 lacs per event in a year. The incentive will be provided to a unit only once over the policy period.
NOTE :–
A. All incentives in the form of reimbursement, subsidies, exemptions etc., will be subject to a maximum of 100% of fixed capital investment made by MSME, Large units in Pharma and Medical Device Sector.
mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 2023 21B. All incentives for eligible mega projects in the form of reimbursement, subsidies, exemptions etc., will be subject to a maximum of 200% of fixed capital investment made by Mega units in Pharma and Medical Device Sector.
13. Ease of Doing Business –
Taking forward the vision and mission of the Uttar Pradesh Industrial Investment and Employment Promotion Policy, 2022, this policy also ensures ease of business and ensures conducive business environment in the state.
13.1. Single Window-All required approvals to units shall be provided under one roof through single window system of the state, directly monitored by the Chief Minister's office.
13.2. Time bound clearances-Providing speedy and time bound clearances is one of the prime intentions of this policy. Towards this goal, timely delivery of services, clearances, approvals, permits, etc. will be made assured through the Act.
13.3. Nodal Officer-Food Safety and Drug Administration (FSDA) will depute nodal officer who will assist investors in the clearance of Pollution NOC, Fire NOC and other NOC/Certificates required to establish pharmaceutical units.
13.4. Pre-Consultation of project plan by FSDA Team-The investor will submit dossier of project and building plan which will be examined by FSDA team to assess the feasibility of project. Letter of Comfort will be issued to the investor after successful scrutiny of dossier.
13.5. Any Bulk Drug Park/Medical Device Parks sanctioned under Central Government Scheme shall be developed by the Industries Development Department.
Incentives for units in such parks, which are other than those provided in the present policy, shall be determined by the Industries Development Department after due approval of the cabinet.
14. Policy Implementation –
Department of Food Safety and Drug Administration will be nodal department for implementation and monitoring of this policy.
14.1. Uttar Pradesh Pharmaceutical Development Cell will be set up as advisory body for technical guidance and support. The Cell will be chaired by Additional Chief Secretary/Principal Secretary, Department of Food Safety and Drug Administration, and consist of representatives from concerned departments and experts from different areas of Pharmaceutical and Biotechnology. Representatives of Industry Associations will be invitee members. The matter referred by the regulatory committees and others will be taken up by the Cell from time to time.
UP Pharmaceutical Development Cell will operate with the following mandate:–
(i) To promote, support and facilitate the overall development of Pharmaceutical and Biotechnology in the State.
(ii) To facilitate the infrastructure development, research, innovation and human resource development.
(iii) To facilitate regional, national and international networking for promotion of Pharmaceutical and biotechnology.
(iv) To facilitate the development of data bank and resource centres.
(v) To facilitate creation of scientific awareness, socio-ethical acceptance, adoption and application of Pharmaceutical and biotechnology.
14.2. Policy Implementation Unit (PIU) will be set up under the Commissioner of Infrastructure and Industrial Development. Under this, applications from micro, small and medium enterprises and large categories will be approved. The PIU will be responsible for making recommendations and approvals for incentives applicable to the units defined under this policy in coordination with the Uttar Pradesh Pharmaceutical Development Cell and provide timely redressal of grievances. The Policy Implementation Unit will consist of Principal Secretaries/Secretaries (as the case may be) of Department of Infrastructure and Industrial Development, Department of Science and Technology, Department of Food Safety and Drug Administration and Department of AYUSH.
22 mRrj izns'k vlk/kkj.k xtV] 4 vxLr] 202314.3. Empowered Committee under the chairmanship of Chief Secretary shall oversee the development of UP Pharmaceutical and Medical Device Industry Policy, 2023 and monitor the implementation of the same. Under this, applications of mega category will be approved. The Additional Chief Secretaries/Principal Secretaries/Secretaries of different departments will be its member. Additional Chief Secretary/Principal Secretary/Secretary (as the case may be) of Food Safety and Drug Administration Department will be the Coordinating Secretary of the Committee. Representatives of the Industry Associations will be invitee members.
14.4. Food Safety and Drug Administration may affiliate one or more than one specialised agencies like-PICUP, UPSIDA or external agency for disposal/verification process of application/ proposals received for the implementation under this policy.
By order,
ANITA SINGH,
Apar Mukhya Sachiv.
ih0,l0;w0ih0&,0ih0 1116 jkti=&2024&¼3113½&599 izfr;k¡ ¼dEI;wVj@Vh0@vkWQlsV½A ih0,l0;w0ih0&,0ih0 1 lk0 [kk| lqj{kk ,oa vkS"kf/k iz'kklu&2024&¼3114½&100 izfr;k¡ ¼Mh0Vh0ih0@vkWQlsV½A